Quadrature Capital’s Anavex Life Sciences AVXL Stock Holding History

Quadrature Capital’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-60,336	Closed	-$185K	–	1597
2026 Q1	$185K	Buy	+60,336	New	+$261K	﹤0.01%	1135

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Quadrature Capital's AVXL Position: Q2 2026 in Review

Quadrature Capital sold out of Anavex Life Sciences (AVXL) in Q2 2026, closing a stake of 60,336 shares — an estimated $185K sold.

Quadrature Capital first reported a position in AVXL in Q1 2026 and held it in 1 quarter. The position peaked at $185K in Q1 2026. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

Quadrature Capital reported no remaining Anavex Life Sciences position as of Q2 2026 after selling out during the quarter.
Quadrature Capital sold 60,336 Anavex Life Sciences shares in Q2 2026, an estimated $185K.
Quadrature Capital first reported a position in Anavex Life Sciences in Q1 2026 and held it in 1 quarter.
Quadrature Capital's Anavex Life Sciences position peaked at $185K in Q1 2026.
179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.